Evidence map›Paper›PMID 42889407›Full record

ReviewFrontiers in immunology2026

Advances in

Xiaoling Ding, Wang Bo, Hongmei Gu, Xia Yang, Jie Yang, Hui Ma, Shan He, Xin Ma, Noun Dara, Xuebing Zhou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoling Ding *People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, China.
Wang Bo *People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, China.
Hongmei GuPeople's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, China.
Xia YangPeople's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, China.
Jie YangPeople's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, China.
Hui MaDepartment of Pharmacy, General Hospital of Ningxia Medical University, Yinchuan, China.
Shan HePeople's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, China.
Xin MaPeople's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, China.
Noun DaraPeople's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, China.
Xuebing ZhouPeople's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune dysregulation critically drives the pathogenesis of inflammation, malignancy, metabolic disorders, and autoimmunity, creating an urgent demand for safe, efficacious immunomodulatory interventions.

Indexed as

GlycyrrhizaImmunologic FactorsPolysaccharidesAnimalsHumansStructure-Activity RelationshipImmunologic FactorsPolysaccharidesGlycyrrhiza polysaccharidesgut microbiotaimmunomodulationstructure-activity relationshiptherapeutic potential

Identifiers

PMID42889407
PMCPMC13670021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.